Company Profile

Laboratorio Farmaceutico Erfo S.p.A. specializes in the formulation, production and marketing of nutraceuticals, resulting from continuous research and development. The activity is organized around 3 poles:
- Diètnatural: a format designed and developed by the company, dedicated to the sale of nutraceutical products dedicated to slimming and continuous assistance through operators specialized in nutrition within the framework of wellness therapy;
- Medical Division: a line of nutraceutical products launched in 2021, dedicated to three specific therapeutic areas (gastroenterology, neurology and musculoskeletal) with major developments planned in the orthopedic field;
- BodySano: a French format integrated in 2023 following the acquisition of a majority interest in BodySano France (now Erfo France) and focused on offering new methods of nutritional coaching associated with the commercialization of dietary supplements and beauty treatments with innovative tools.


Source: Cofisem - Last Update: 2024-09-02

Key Executives
Chairman and Chief Executive Officer Alessandro Cutè
Head of Investor Relations Daniele Travisano
Chief Financial Officer Daniele Travisano


Source: Cofisem - Last Update: 2024-09-02

Key Figures
Millenium 2023 2022 2021 2020 2019
Net sales 5,737,059 4,624,287 4,818,434 3,904,323 4,348,805
Consumed purchases 1,662,370 1,319,870 1,370,627 1,078,758 1,188,229
Labour costs 1,036,069 890,572 694,251 654,178 772,173
Operating profit 836,742 987,032 1,580,046 1,487,526 1,807,954
Income tax 224,830 232,433 389,859 350,878 483,776
Net income 590,330 716,072 1,165,976 1,139,930 1,310,094
Net income (Group share) 553,815 716,072 1,165,976 1,139,930 1,310,094
Fiscal year end 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - unit EUR - unit EUR - unit EUR - unit EUR - unit
Account Standards Local GAAP Local GAAP Local GAAP Local GAAP Local GAAP

Source: Cofisem - Last Update: 2024-09-02

Shareholder information
Active Capital Investment 75.74 %
Group-owned stock 5.14 %
Free float 19.12 %


Source: Cofisem - Last Update: 2024-09-02

Contact

Daniele Travisano
Phone number: 090 914 6125
IR@ERFO.IT


Source: Laboratorio Farmaceutico Erfo S.p.A. - Last Update: 2024-09-02

Please contact MyQuestion.Italy@euronext.com for Company Profile support.

Quotazioni, Book, Dividendi, Documenti Societari, Corporate Governance, Internal Dealing di Laboratorio Farmaceutico Erfo


The Exchange accepts no responsability for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.


You will be redirected in five seconds.